Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Primary Target | Pathway | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|---|---|
| SUM1315MO2 | Topotecan | 0.31623 | Topo I | Chemotherapy | 0.0757 | 0.27421 |
| SUM1315MO2 | Topotecan | 1.0 | Topo I | Chemotherapy | 0.0082 | 0.26233 |
| SUM1315MO2 | Topotecan | 3.1623 | Topo I | Chemotherapy | -0.1166 | 0.33834 |
| SUM1315MO2 | Topotecan | 10.0 | Topo I | Chemotherapy | -0.3317 | 0.37487 |
| SUM1315MO2 | Etoposide | 0.0010833 | Topo II | Chemotherapy | 1.0966 | -0.00816 |
| SUM1315MO2 | Etoposide | 0.0033333 | Topo II | Chemotherapy | 0.9789 | -0.00489 |
| SUM1315MO2 | Etoposide | 0.01 | Topo II | Chemotherapy | 0.9170 | 0.00105 |
| SUM1315MO2 | Etoposide | 0.031667 | Topo II | Chemotherapy | 0.8017 | 0.00795 |
| SUM1315MO2 | Etoposide | 0.1 | Topo II | Chemotherapy | 0.7647 | 0.05638 |
| SUM1315MO2 | Etoposide | 0.31623 | Topo II | Chemotherapy | 0.3952 | 0.18014 |
| SUM1315MO2 | Etoposide | 1.0 | Topo II | Chemotherapy | 0.3188 | 0.21102 |
| SUM1315MO2 | Etoposide | 3.1623 | Topo II | Chemotherapy | 0.2357 | 0.26913 |
| SUM1315MO2 | Etoposide | 10.0 | Topo II | Chemotherapy | 0.0416 | 0.26598 |
| SUM1315MO2 | Dasatinib | 0.001 | BCR/ABL | MAPK/nRTK | 0.8112 | 0.01309 |
| SUM1315MO2 | Dasatinib | 0.0031623 | BCR/ABL | MAPK/nRTK | 0.6705 | 0.01349 |
| SUM1315MO2 | Dasatinib | 0.01 | BCR/ABL | MAPK/nRTK | 0.6067 | 0.02265 |
| SUM1315MO2 | Dasatinib | 0.031623 | BCR/ABL | MAPK/nRTK | 0.5093 | 0.03931 |
| SUM1315MO2 | Dasatinib | 0.1 | BCR/ABL | MAPK/nRTK | 0.2142 | 0.09466 |
| SUM1315MO2 | Dasatinib | 0.31623 | BCR/ABL | MAPK/nRTK | 0.0501 | 0.15710 |
| SUM1315MO2 | Dasatinib | 1.0 | BCR/ABL | MAPK/nRTK | -0.0940 | 0.23902 |
| SUM1315MO2 | Dasatinib | 3.1623 | BCR/ABL | MAPK/nRTK | -0.1622 | 0.26947 |
| SUM1315MO2 | Dasatinib | 10.0 | BCR/ABL | MAPK/nRTK | -0.2366 | 0.34182 |
| SUM1315MO2 | Trametinib | 0.0001 | MEK | MAPK/nRTK | 1.0390 | 0.00491 |
| SUM1315MO2 | Trametinib | 0.00031623 | MEK | MAPK/nRTK | 1.0048 | 0.00336 |
| SUM1315MO2 | Trametinib | 0.001 | MEK | MAPK/nRTK | 0.9901 | 0.01206 |